Loading...
Although the new triple regimens are effective for the treatment of patients with chronic hepatitis C virus (HCV) infection, they have been linked to serious adverse events. Interferon — the backbone of all current therapies — is a major contributor to these effects. Now, researchers have conducted an industry-sponsored, phase Ib, international, open-label trial to evaluate the efficacy and safety of an interferon-free regimen.
Treatment-naive adults with HCV genotype 1 infection were randomized to receive 4 weeks of therapy with either 400 mg or 600 mg of BI 207127 (a nonnucleoside polymerase inhibitor, 3 times daily). Patients also received BI 201335 (a protease inhibitor, 120 mg once daily) and ribavirin (1000 mg or 1200 mg daily). The pr…